# Revolution Medicines Breakthrough in Pancreatic Cancer

Page: https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192/revolution-medicines-breakthrough-in-pancreatic-cancer
Text version: https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192/revolution-medicines-breakthrough-in-pancreatic-cancer.md
Podcast: [Business News Today | 2 Min News | The Daily News Now!](https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192)
Published: 2026-06-11T11:31:51+00:00
Episode link: https://api.fastcast.ai/audio/6bdc203a-8ad0-42fb-995d-31df8ad25922.mp3
Audio file: https://api.fastcast.ai/audio/6bdc203a-8ad0-42fb-995d-31df8ad25922.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/business-finance-news-today-2-min-news-the-daily-news-now-7726192/episodes/revolution-medicines-breakthrough-in-pancreatic-cancer
Duration seconds: 130

## Resource

Revolution Medicines is rewriting the pancreatic cancer playbook with daraxonrasib, the first drug to push median survival past a year in metastatic cases—so groundbreaking it earned a standing ovation from oncologists. Now in commercial rollout mode, the company’s FDA submission is underway, while major cancer centers already treat patients via its Expanded Access Program. Targeting the RAS protein, which drives 90% of pancreatic tumors, daraxonrasib is also being tested in colorectal and lung cancers. With a pipeline of other RAS inhibitors like zoldonrasib and elironrasib, Revolution’s science hinges on a novel chaperone-binding approach. Though still unprofitable, the company’s $4 billion cash reserve gives it a two-year runway to market daraxonrasib without fundraising—and makes it a hot acquisition target. It’s a high-stakes, high-reward biotech play: massive potential upside if execution succeeds, but risk if the science or commercialization falters. Support the show: Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN: advertise@thednn.ai This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai. View sources & latest updates: https://sources.thednn.ai/4fc3a5981f2532b2

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/business-finance-news-today-2-min-news-the-daily-news-now-7726192/episodes/revolution-medicines-breakthrough-in-pancreatic-cancer/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192/revolution-medicines-breakthrough-in-pancreatic-cancer.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.